MannKind Corp
MNKDHealthcare|Biotechnology|USA
$4.09
-0.05 (-1.21%)
About
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Stock Price
+7.6%(1Y)
Pipeline Summary
64 total trials23
Phase 1
16
Phase 2
15
Phase 3
6
Phase 4
Terminated: 8Withdrawn: 1Recruiting: 6Completed: 46Unknown: 2NO_LONGER_AVAILABLE: 1
Active Trials (6)
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
NCT07679893Idiopathic Pulmonary Fibrosis
Phase 2Recruiting
Enrollment: 210 participants
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
NCT07344558Idiopathic Pulmonary Fibrosis (IPF)
Phase 1Recruiting
Enrollment: 24 participants
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
NCT06532942Healthy Volunteers
Phase 1Recruiting
Enrollment: 40 participants
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
NCT06535789Diabetes, Gestational
Phase 2Phase 3Recruiting
Enrollment: 30 participants
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery
NCT06880835Diabetes Mellitus, Type 1
N/ARecruiting
Enrollment: 30 participants
BioScore
4.2/10
Cautious
Ownership
Recent Insider Trades
Binder Steven B.SELL
2026-05-1216,940 shares @ $3.29
Thomson DavidSELL
2026-05-123,033 shares @ $3.29
Castagna MichaelBUY
2026-03-10100,000 shares @ $2.59
Tross Stuart ASELL
2026-01-0847,006 shares @ $6.33
Castagna MichaelSELL
2025-12-1765,804 shares @ $6.01
Data last updated: Jul 13, 2026, 12:47 PM